Positive News SentimentPositive NewsNASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis $0.68 -0.05 (-6.51%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Genenta Science Stock (NASDAQ:GNTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genenta Science alerts:Sign Up Key Stats Today's Range$0.67▼$0.7550-Day Range$0.65▼$1.3352-Week Range$0.55▼$10.00Volume76,824 shsAverage Volume818,760 shsMarket Capitalization$15.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment. Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues. Temferon is an investigational product and has not been approved for commercial use. Genenta was established in Italy as a spin-off of the San Raffaele Scientific Institute in Milan, building on research associated with Professor Luigi Naldini and his laboratory. The company is headquartered in Milan and has pursued clinical development internationally, including in the United States and Europe. Pierluigi Paracchi has been associated with the company’s founding and executive leadership.AI Generated. May Contain Errors. Read More Genenta Science Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreGNTA MarketRank™: 1.136453266725 of 5 starsGenenta Science scored higher than 23% of companies evaluated by MarketBeat, and ranked 803rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGenenta Science has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGenenta Science has only been the subject of 1 research reports in the past 90 days.Read more about Genenta Science's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGenenta Science has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.66% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 1.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently decreased by 7.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenenta Science does not currently pay a dividend.Dividend GrowthGenenta Science does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentGenenta Science has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genenta Science this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genenta Science insiders have not sold or bought any company stock.Percentage Held by Insiders28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.13% of the stock of Genenta Science is held by institutions.Read more about Genenta Science's insider trading history. Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNTA Stock News HeadlinesSòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into OrbitSeptember 15, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | finanznachrichten.deI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | finanznachrichten.deGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | globenewswire.comGenenta Science SPA ADR GNTAJuly 12, 2026 | morningstar.comMGENENTA SCIENCE SPA: Genenta signs Definitive Agreements with Sophia High TechApril 23, 2026 | finanznachrichten.deSee More Headlines GNTA Stock Analysis - Frequently Asked Questions How have GNTA shares performed this year? Genenta Science's stock was trading at $1.49 at the beginning of the year. Since then, GNTA stock has decreased by 53.7% and is now trading at $0.69. How were Genenta Science's earnings last quarter? Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) released its quarterly earnings data on Tuesday, March, 31st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.29. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an initial public offering on Tuesday, December 14th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2026Today10/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, GNTA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GNTA CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees9Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.52Miscellaneous Outstanding Shares23,590,000Free Float16,752,000Market Cap$15.92 million OptionableNot Optionable Beta0.76 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:GNTA) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...Crypto 101 Media | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
